Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030877 | PMC |
| http://dx.doi.org/10.1503/cmaj.74120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Substance use and psychiatric outcomes following substance use disorder treatment: An 18-month prospective cohort study in Chile.
Addiction
January 2025
Center for Studies on Justice and Society (CJS), Pontificia Universidad Católica de, Chile.
Background And Aims: Evidence from high-income countries has linked duration and compliance with treatment for substance use disorders (SUDs) with reductions in substance use and improvements in mental health. Generalizing these findings to other regions like South America, where opioid and injection drug use is uncommon, is not straightforward. We examined if length of time in treatment and compliance with treatment reduced subsequent substance use and presence of psychiatric comorbidities.
View Article and Find Full Text PDFObjective: In October 2018, the Government of Canada legalized cannabis for recreational use nationwide. The effects of legalization on cannabis use have been primarily assessed through cross-sectional surveys.
Method: In the present study, a two-wave longitudinal design was used to explore potential demographic, substance use and behavioral addiction, and mental health predictors of change in cannabis use status following legalization.
Objective: The present research evaluated the impact of legalizing recreational cannabis among individuals with substance use disorders (SUDs) who may already use cannabis at high rates.
Method: Using an interrupted time series study design, we evaluated the potential impact of legalizing recreational cannabis among individuals seeking treatment for SUD within a hospital-based treatment setting in Guelph, Ontario. We examined 2,925 individuals who entered an inpatient SUD treatment program between April 2017 and December 2021.
Predictors of Response to Medical Cannabis for Chronic Pain: A Retrospective Review of Real-Time Observational Data.
Cannabis
December 2024
Department of Anesthesia, McMaster University.
Objective: People living with chronic pain increasingly use medical cannabis for symptom relief. We conducted a retrospective cohort study examining cannabis for chronic pain relief using anonymous archival data obtained from the medicinal cannabis tracking app, Strainprint®.
Method: We acquired cannabis utilization data from 741 adults with chronic pain and used multilevel modeling to examine the association of age, sex, type of pain (muscle, joint or nerve pain), cannabis formulation (high CBD, balanced CBD:THC, or high THC), route of administration (inhaled or ingested), cannabis use before vs.
CBD and the 5-HT1A receptor: A medicinal and pharmacological review.
Biochem Pharmacol
January 2025
Department of Biomedical Sciences, College of Medicine, University of Houton, Houston, TX, 77204, USA. Electronic address:
Cannabidiol (CBD), a phytocannabinoid, has emerged as a promising candidate for addressing a wide array of symptoms. It has the ability to bind multiple proteins and receptors, including 5-HT1AR, transient receptor potential vanilloid 1 (TRPV1), and cannabinoid receptors. However, CBD's pharmacodynamic interaction with 5-HT1AR and its medicinal outcomes are still debated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!